The Burden of Pertussis Hospitalization in HIV-Exposed and HIV-Unexposed South African Infants
Overview
Authors
Affiliations
Background: There are limited data on pertussis in African children, including among human immunodeficiency virus (HIV)-exposed infants. We conducted population-based hospital surveillance to determine the incidence and clinical presentation of Bordetella pertussis-associated hospitalization in perinatal HIV-exposed and -unexposed infants.
Methods: Children <12 months of age hospitalized with any sign or symptom of respiratory illness (including suspected sepsis or apnea in neonates) were enrolled from 1 January 2015 to 31 December 2015. Detailed clinical and demographic information was recorded and respiratory samples were tested by polymerase chain reaction (PCR).
Results: The overall B. pertussis PCR positivity was 2.3% (42/1839), of which 86% (n = 36) occurred in infants <3 months of age. Bordetella pertussis was detected in 2.1% (n = 26/1257) of HIV-unexposed and 2.7% (n = 16/599) of HIV-exposed infants. The incidence (per 1000) of B. pertussis-associated hospitalization was 2.9 (95% confidence interval [CI], 1.8-4.5) and 1.9 (95% CI, 1.3-2.6) in HIV-exposed and HIV-unexposed infants, respectively (P = .09). The overall in-hospital case fatality ratio among the cases was 4.8% (2/42), both deaths of which occurred in HIV-exposed infants <3 months of age. Among cases, presence of cough ≥14 days (20.5%) and paroxysmal coughing spells (33.3%) at diagnosis were uncommon. Only 16 (38%) B. pertussis-associated hospitalizations fulfilled the Centers for Diseases Control and Prevention case definition of "definite" pertussis.
Conclusions: Bordetella pertussis contributed to a modest proportion of all-cause respiratory illness hospitalization among black-African children, with a trend for higher incidence among HIV-exposed than HIV-unexposed infants. Maternal vaccination of pregnant women should be considered to reduce the burden of pertussis hospitalization in this population.
Nakabembe E, Greenland M, Amaral K, Abu-Raya B, Amone A, Andrews N Lancet Glob Health. 2024; 13(1):e81-e97.
PMID: 39706666 PMC: 11659843. DOI: 10.1016/S2214-109X(24)00409-1.
Genomic characterization of in South Africa, 2015-2019.
Moosa F, du Plessis M, Weigand M, Peng Y, Mogale D, de Gouveia L Microb Genom. 2023; 9(12).
PMID: 38117675 PMC: 10763497. DOI: 10.1099/mgen.0.001162.
Verwey C, Ramocha L, Laubscher M, Baillie V, Nunes M, Gray D BMJ Open Respir Res. 2023; 10(1).
PMID: 37169402 PMC: 10186461. DOI: 10.1136/bmjresp-2023-001618.
Moosa F, Tempia S, Kleynhans J, McMorrow M, Moyes J, du Plessis M Emerg Infect Dis. 2023; 29(2):294-303.
PMID: 36692337 PMC: 9881781. DOI: 10.3201/eid2902.221125.
Zar H, Moore D, Andronikou S, Argent A, Avenant T, Cohen C Afr J Thorac Crit Care Med. 2021; 26(3).
PMID: 34471872 PMC: 7433705. DOI: 10.7196/AJTCCM.2020.v26i3.104.